On August 13, 2019 Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, reported recent achievements the company has completed as a part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex immunogene therapy, to commercialization (Press release, Genprex, AUG 13, 2019, View Source [SID1234538654]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These recent achievements are outlined in the company’s newly launched, interactive corporate timeline, which can be found on Genprex’s website.

"Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth of our team to support these initatives," said Rodney Varner, Chairman and Chief Executive Officer of Genprex. "These accomplishments have set the stage for us to continue on our path of growth and expansion, enabling our efforts to bring our drug candidate to market for lung cancer patients who cannot benefit from today’s therapies."

Genprex’s updates to ongoing activities, include:

Q2 2019

Announced positive pre-clinical findings from MD Anderson Cancer Center Sponsored Research Agreement studying the effects of TUSC2 with pembrolizumab at American Association of Cancer Research meeting
Developed Oncoprex and immunotherapy combination clinical trial design
Collaborated with Addison Whitney for drug nomenclature branding program and submission of non-proprietary drug name selections
Initiated manufacturing process development with key manufacturing partners to support clinical expansion and manufacturing scale-up processes
Completed manufacturing of TUSC2 DNA plasmid to support clinical trial ramp-up
Q1 2019

Appointed Key Staff: Senior Director of Pharmaceutical Sciences and Manufacturing and Senior Manager of Communications and Marketing
USPTO issued two additional patents to add to our intellectual property portfolio
Identified potential new clinical sites for expansion of Oncoprex and erlotinib combination clinical trial
Q4 2018

Appointed Key Staff: VP of Clinical Operations
Completion of clinical data reconciliation within a CDISC/SDTM-compliant database
Q3 2018

Initiated clinical site selection and expansion program with CRO partner
Initialization of sponsored pre-clinical research with MD Anderson Cancer Center to evaluate TUSC2 with immunotherapies including immune checkpoint inhibitors anti-PD1 and CTLA-4
Q2 2018

Continued execution and enhancement of strategy for manufacturing technology transfer and scale-up initiatives
Genprex’s new interactive timeline on its website shares additional historical achievements, where visitors can follow the company’s success since its inception.